Description: Britannia Pharmaceuticals is a UK based global speciality pharmaceutical company specialising in treatments for Parkinson's disease and Schizophrenia.
For more than 30 years, our primary field of interest has been the development of innovative, patient-centric technology that effectively delivers therapies to people with Parkinson’s disease.
We work with specialist focus groups, fund clinical trials and invest in care initiatives that optimise treatment programmes to improve quality of life.
Britannia Pharmaceuticals Ltd. is dedicated to improving the lives of people with long-term neurological conditions, and providing important support for their families, caregivers, and medical teams.